Myriad Genetics, Inc. (NASDAQ:MYGN) insider Nicole Lambert sold 4,354 shares of Myriad Genetics stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $19.73, for a total value of $85,904.42. Following the completion of the sale, the insider now owns 59,150 shares in the company, valued at $1,167,029.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
MYGN opened at $19.42 on Friday. The stock has a market cap of $1.45 billion, a PE ratio of -53.94, a PEG ratio of 11.31 and a beta of 0.99. The company has a quick ratio of 2.61, a current ratio of 2.86 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average of $26.85 and a 200-day moving average of $28.17. Myriad Genetics, Inc. has a 52 week low of $19.08 and a 52 week high of $48.40.
Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Thursday, February 6th. The company reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.01. The company had revenue of $195.10 million during the quarter, compared to analysts’ expectations of $209.61 million. Myriad Genetics had a positive return on equity of 5.42% and a negative net margin of 3.22%. The firm’s revenue for the quarter was down 10.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.38 EPS. Equities analysts anticipate that Myriad Genetics, Inc. will post 0.15 EPS for the current year.
A number of brokerages have recently weighed in on MYGN. Zacks Investment Research lowered Myriad Genetics from a “hold” rating to a “sell” rating and set a $21.00 price objective on the stock. in a research report on Thursday. JPMorgan Chase & Co. cut their price objective on Myriad Genetics from $20.00 to $17.00 and set an “underweight” rating on the stock in a research report on Friday, February 7th. Piper Jaffray Companies cut their price objective on Myriad Genetics from $40.00 to $22.00 in a research report on Tuesday, November 5th. Piper Sandler cut their price objective on Myriad Genetics from to in a research report on Friday, February 7th. Finally, Needham & Company LLC began coverage on Myriad Genetics in a research report on Friday, January 3rd. They issued a “strong-buy” rating and a $36.00 price objective on the stock. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $25.16.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fisher Asset Management LLC lifted its stake in shares of Myriad Genetics by 31.3% in the 3rd quarter. Fisher Asset Management LLC now owns 181,155 shares of the company’s stock valued at $5,186,000 after purchasing an additional 43,225 shares during the period. Comerica Bank lifted its stake in shares of Myriad Genetics by 0.4% in the 3rd quarter. Comerica Bank now owns 109,680 shares of the company’s stock valued at $3,585,000 after purchasing an additional 463 shares during the period. New York State Teachers Retirement System lifted its stake in shares of Myriad Genetics by 39.7% in the 4th quarter. New York State Teachers Retirement System now owns 73,898 shares of the company’s stock valued at $2,012,000 after purchasing an additional 21,000 shares during the period. Royal Bank of Canada lifted its stake in shares of Myriad Genetics by 196.5% in the 2nd quarter. Royal Bank of Canada now owns 13,229 shares of the company’s stock valued at $368,000 after purchasing an additional 8,767 shares during the period. Finally, CWM LLC lifted its stake in shares of Myriad Genetics by 2.2% in the 4th quarter. CWM LLC now owns 610,279 shares of the company’s stock valued at $16,618,000 after purchasing an additional 12,944 shares during the period.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Article: What is the accumulation/distribution indicator?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.